Dow AgroSciences

Faster Efforts

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

The technology is based on engineered zinc finger DNA-binding proteins, which bind to specific functional domains to create transcription factors capable of activating or repressing target genes.

The funding will support support two alliances between industry and academia that are applying genomic technologies to agriculture and healthcare.

The deal expands the companies' ongoing collaboration, which began in mid-2015, to include additional natural product targets in crop protection and traits.

Critical Path will license Dow AgroScience's Plextein technology for multiplex detection of plant proteins using mass spectroscopy and provide it as a service.

The company will work with the Institute of Crop Sciences of the Chinese Academy of Agricultural Sciences to develop the technology into a rice genome-editing platform.

In the study, company researchers explored treating corn rootworms with RNAi molecules that would interfere with the viability of their offspring.

The companies will work together to discover and develop natural products for crop protection.

NEW YORK (GenomeWeb) – In Nature Genetics, an international team led by investigators at the National Institute on Aging presented findings from a meta-analysis of Parkinson's disease genome-wi

NEW YORK (GenomeWeb) – Dow AgroSciences said today that Sigma-Aldrich will manufacture and supply zinc finger nuclease reagents for use with Dow AgroSciences' Exzact Precision Technology, a genome modification platform for plants.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.